BMC Gastroenterology Гастроэнтерология

Apigenin mitigates intestinal barrier dysfunction in sepsis by modulating the AKT signaling pathway

Zheng Lijun, Wang Liping, Zhao Dandan, Zhao Wenjie, Xu Renjie, Ji Xueyan, Che Wenqing, Li Chen, Zhao Lu
Springer Nature · 2025-08-30 · DOI 10.1186/s12876-025-04196-0

Аннотация

Abstract Sepsis is a systemic inflammatory response syndrome triggered by infection, which can lead to multiple organ dysfunction. This study untangles the synergistic multi-mechanistic effects of the natural flavonoid apigenin in ameliorating this pathological process. Utilizing a murine sepsis model and Caco-2 cell line, we systematically investigated the impact of apigenin on intestinal barrier function. Apigenin treatment (50 mg/kg) markedly improved intestinal barrier integrity, as shown by reduced serum FITC-dextran levels and restored expression of tight junction proteins Occludin, Claudin-1, and ZO-1. The compound simultaneously attenuated systemic inflammation by lowering IL-6 and TNF-α levels. Network pharmacology and molecular docking identified AKT1 and MMP-9 as key molecular targets of apigenin, which was experimentally validated through observed suppression of MMP-9 and COX-2 protein expression. These results demonstrate apigenin’s capacity to preserve intestinal barrier function during sepsis through coordinated anti-inflammatory and barrier-repair mechanisms.

Читать у издателя →